Abstracts
A Phase 1-2 Trial of Concurrent Radiation Therapy, Cisplatin and BMX-001 in Locally Advanced Head and Neck Cancer. Brizel DM at al. ASTRO 2021 Link to abstract.
The Phase I Results of A Phase 1/2 Trial for Patients with Newly Diagnosed Anal
Cancer Treated with Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001. Lin C et al. ASTRO 2021 Link to abstract.
Clinical Trials in Progress: BMX-HGG: Phase 2 Trial of Newly Diagnosed High-Grade Glioma Treated with Concurrent Radiation Therapy, Temozolomide, and BMX-001. Peters et al. ASCO 2021. Link to abstract.
Preserving Neurocognition without Compromising Tumor Control during Whole-Brain Radiotherapy Therapy in Patients with Numerous Brain Metastases via a Novel Superoxide Dismutase Mimetic: Initial Safety Lead-In and Design of a Clinical Trial. Kirkpatrick J et al. ASTRO 2020. Link to abstract.
61st American Society for Radiation Oncology Annual Meeting (ASTRO), September 2019, Chicago, IL. First in Human Clinical Trial of a Metalloporphyrin Dual Radioprotectant and Radiosensitizer, BMX-001, in Newly Diagnosed High-Grade Glioma undergoing Concurrent Chemoradiation
Abstract for the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 – Jun 2, 2020, Chicago, IL, Clinical Trials In Progress: BMX-HGG: Phase 2 Trial of Newly Diagnosed High Grade Glioma Treated with Concurrent Radiation Therapy, Temozolomide, and BMX-001
The 2020 MASCC/ISOO Annual Meeting, SEVILLE, SPAIN, 25-27 June, 2020 is postponed to 24-26 June 2021 in the same location – Seville, Spain. Title: Cognitive Outcomes of Phase 1 Trial of Novel Metalloporphyrin Radioprotectant and Radiosensitizer in Newly Diagnosed High Grade Glioma Patients